Cargando…
The efficacy and safety of azithromycin in asthma: A systematic review
Azithromycin is a potential therapeutic choice for asthma control, which is a heterogeneous airway inflammatory disease. Because of variable findings, we intend to evaluate the therapeutic effect and safety of azithromycin in asthma. Databases, including PubMed, EMBASE, Cochrane, and CNKI until 31 D...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378181/ https://www.ncbi.nlm.nih.gov/pubmed/30661297 http://dx.doi.org/10.1111/jcmm.13919 |
_version_ | 1783395879203373056 |
---|---|
author | Tian, Bao‐Ping Xuan, Nanxia Wang, Yesong Zhang, Gensheng Cui, Wei |
author_facet | Tian, Bao‐Ping Xuan, Nanxia Wang, Yesong Zhang, Gensheng Cui, Wei |
author_sort | Tian, Bao‐Ping |
collection | PubMed |
description | Azithromycin is a potential therapeutic choice for asthma control, which is a heterogeneous airway inflammatory disease. Because of variable findings, we intend to evaluate the therapeutic effect and safety of azithromycin in asthma. Databases, including PubMed, EMBASE, Cochrane, and CNKI until 31 December 2017, were searched to identify available randomised controlled trials regarding azithromycin treatment for asthma. We identified seven studies involving 1520 cases that met our criteria. The mean difference for lung function (FEV (1), FVC, PEF), symptom assessment (ACQ, AQLQ), airway inflammation, and risk ratios for adverse events were extracted. Chi‐square and I (2) tests were applied to evaluate the heterogeneity among the studies towards each index with a random effect model or a fixed effect model. Pooled analysis shows that azithromycin administration results in no significant improvement in FEV (1) (MD: 0.09, 95% CI −0.10 to 0.29, P = 0.36), PEF (MD: 11.76; 95% CI, −2.86 to 26.38, P = 0.11), total airway inflammatory cells (MD: −0.29; 95% CI, −1.38 to 0.80, P = 0.60), ACQ (MD: 0.05; 95% CI, −0.08 to 0.19, P = 0.44), and AQLQ (MD: 0.12; 95% CI, −0.02 to 0.26, P = 0.10). Moreover, no significant difference was detected in adverse events (Risk ratio 0.99; 95% CI, 0.82‐1.19, P = 0.90). These findings demonstrate no beneficial clinical outcome of azithromycin in asthma control, and we propose that further prospective cohorts are warranted. |
format | Online Article Text |
id | pubmed-6378181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63781812019-03-01 The efficacy and safety of azithromycin in asthma: A systematic review Tian, Bao‐Ping Xuan, Nanxia Wang, Yesong Zhang, Gensheng Cui, Wei J Cell Mol Med Reviews Azithromycin is a potential therapeutic choice for asthma control, which is a heterogeneous airway inflammatory disease. Because of variable findings, we intend to evaluate the therapeutic effect and safety of azithromycin in asthma. Databases, including PubMed, EMBASE, Cochrane, and CNKI until 31 December 2017, were searched to identify available randomised controlled trials regarding azithromycin treatment for asthma. We identified seven studies involving 1520 cases that met our criteria. The mean difference for lung function (FEV (1), FVC, PEF), symptom assessment (ACQ, AQLQ), airway inflammation, and risk ratios for adverse events were extracted. Chi‐square and I (2) tests were applied to evaluate the heterogeneity among the studies towards each index with a random effect model or a fixed effect model. Pooled analysis shows that azithromycin administration results in no significant improvement in FEV (1) (MD: 0.09, 95% CI −0.10 to 0.29, P = 0.36), PEF (MD: 11.76; 95% CI, −2.86 to 26.38, P = 0.11), total airway inflammatory cells (MD: −0.29; 95% CI, −1.38 to 0.80, P = 0.60), ACQ (MD: 0.05; 95% CI, −0.08 to 0.19, P = 0.44), and AQLQ (MD: 0.12; 95% CI, −0.02 to 0.26, P = 0.10). Moreover, no significant difference was detected in adverse events (Risk ratio 0.99; 95% CI, 0.82‐1.19, P = 0.90). These findings demonstrate no beneficial clinical outcome of azithromycin in asthma control, and we propose that further prospective cohorts are warranted. John Wiley and Sons Inc. 2019-01-19 2019-03 /pmc/articles/PMC6378181/ /pubmed/30661297 http://dx.doi.org/10.1111/jcmm.13919 Text en © 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Tian, Bao‐Ping Xuan, Nanxia Wang, Yesong Zhang, Gensheng Cui, Wei The efficacy and safety of azithromycin in asthma: A systematic review |
title | The efficacy and safety of azithromycin in asthma: A systematic review |
title_full | The efficacy and safety of azithromycin in asthma: A systematic review |
title_fullStr | The efficacy and safety of azithromycin in asthma: A systematic review |
title_full_unstemmed | The efficacy and safety of azithromycin in asthma: A systematic review |
title_short | The efficacy and safety of azithromycin in asthma: A systematic review |
title_sort | efficacy and safety of azithromycin in asthma: a systematic review |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378181/ https://www.ncbi.nlm.nih.gov/pubmed/30661297 http://dx.doi.org/10.1111/jcmm.13919 |
work_keys_str_mv | AT tianbaoping theefficacyandsafetyofazithromycininasthmaasystematicreview AT xuannanxia theefficacyandsafetyofazithromycininasthmaasystematicreview AT wangyesong theefficacyandsafetyofazithromycininasthmaasystematicreview AT zhanggensheng theefficacyandsafetyofazithromycininasthmaasystematicreview AT cuiwei theefficacyandsafetyofazithromycininasthmaasystematicreview AT tianbaoping efficacyandsafetyofazithromycininasthmaasystematicreview AT xuannanxia efficacyandsafetyofazithromycininasthmaasystematicreview AT wangyesong efficacyandsafetyofazithromycininasthmaasystematicreview AT zhanggensheng efficacyandsafetyofazithromycininasthmaasystematicreview AT cuiwei efficacyandsafetyofazithromycininasthmaasystematicreview |